Olmesartan/Hct Krka (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan/Hct acts on the renin‑angiotensin‑aldosterone system to lower elevated blood pressure.

• Hypertension: provides sustained reduction of systolic and diastolic blood pressure in essential hypertension.
• Hypertension with fluid retention: enhances diuretic effect to control volume overload.
• High‑risk cardiovascular patients: contributes to risk reduction when combined with lifestyle measures.

• Olmesartan medoxomil selectively blocks the AT1 subtype of angiotensin II receptors, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting natriuresis and diuresis. The combined actions reduce peripheral vascular resistance and plasma volume, resulting in lower arterial pressure.

Common Side Effects

• Dizziness: mild to moderate light‑headedness, especially after the first dose.
• Headache: transient cephalic discomfort.
• Fatigue: general tiredness without specific cause.
• Increased urination: due to the diuretic component.
• Electrolyte imbalance: mild changes in potassium or sodium levels.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing fainting.
• Acute renal impairment: sudden decrease in kidney function.
• Hyperkalemia: elevated potassium that may affect cardiac rhythm.
• Angioedema: swelling of face, lips, tongue, or airway.
• Life‑threatening electrolyte disturbances: severe hyponatremia or hypokalemia.

Olmesartan/Hct should be used with careful clinical monitoring.

• Blood pressure monitoring: check regularly to avoid excessive lowering.
• Renal function assessment: evaluate serum creatinine before and during therapy.
• Electrolyte surveillance: monitor sodium and potassium levels, especially with diuretic use.
• Pregnancy avoidance: contraindicated in the second and third trimesters due to fetal risk.
• Elderly dose consideration: start with lower dose and titrate cautiously.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan/Hct may interact with several medicines that affect blood pressure, renal function, or electrolyte balance.

Major Interactions (Avoid)

• Aliskiren (in diabetic patients): risk of renal dysfunction and hyperkalemia.
• Potassium‑sparing diuretics: may cause dangerous hyperkalemia.
• Lithium: increased lithium levels and toxicity.
• ACE inhibitors: additive effect on potassium and renal function.
• NSAIDs: may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• Other antihypertensives: may require dose adjustment to prevent hypotension.
• Non‑potassium‑sparing diuretics: monitor electrolytes.
• Antidiabetic agents: blood glucose may improve, requiring dose changes.
• CYP450 inhibitors (e.g., azole antifungals): may increase olmesartan levels.
• Antacids containing aluminum or magnesium: may reduce absorption of olmesartan.